<DOC>
	<DOCNO>NCT01455012</DOCNO>
	<brief_summary>Periodic Limb Movements ( PLMs ) sleep patient Restless Legs Syndrome ( RLS ) show associated elevation Blood Pressure ( BP ) . Rotigotine show effectively reduce incidence PLMs patient RLS . The current study aim demonstrate treatment Rotigotine could help reduce number nocturnal BP elevation associate PLMs patient RLS .</brief_summary>
	<brief_title>Effects Neupro Cardiovascular Observations Patients With Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject inform give ample time opportunity think her/his participation give her/his write informed consent Subject understand investigational nature study willing able comply study requirement . Subject willing accept he/she might treat placebo Treatment Period Subject able apply/remove study patch correctly Subject male female , ≥18 ≤75 year age Subject meet diagnosis idiopathic Restless Legs Syndrome ( RLS ) base 4 essential clinical feature accord International Restless Legs Syndrome Study Group ( Allen et al,2003 ) : 1 . An urge move leg , usually accompany cause uncomfortable unpleasant sensation leg ( The urge move present without uncomfortable sensation . Arms body part also affect ) 2 . The urge move unpleasant sensation begin worsen period rest inactivity , lie sit 3 . The urge move unpleasant sensation partially totally relieved movement , walk stretch , least long activity continue 4 . The urge move unpleasant sensation worse even night day occur even night ( When symptom severe , worsen night may noticeable must previously present ) Subject score ≥11 RLSDiagnostic Index ( RLSDI ) ( Benes Kohnen , 2009 ) Subject initial response previous dopaminergic treatment RLS previous dopaminergic treatment ( ie , de novo ) The subject 's Body Mass Index ( BMI ) ≥18 kg/m^2 ≤35 kg/m^2 At Baseline subject score ≥15 IRLS ( indicate moderate severe RLS ) At Baseline subject score ≥4 point CGI Item 1 assessment ( indicate moderately ill ) At Baseline subject score ≥15 PLM/h Periodic Limb Movements Index ( PLMI ) base polysomnography ( PSG ) ( record second night ) assess investigator Subjects concomitant dose antihypertensive stable dose least 4 week prior Baseline hypertension reasonably control subject agrees continue dose duration study , subject receive concomitant treatment antihypertensive least 4 week prior Baseline intend start use study Subject RLS due renal insufficiency ( uremia ) , iron deficiency anemia , rheumatoid arthritis Subject RLS associate previous concomitant therapy dopamine D2 receptor antagonist , butyrophenones , metoclopramide , atypical antipsychotic ( eg , olanzapine ) , tri tetracyclic antidepressant , mianserine , lithium H2blockers ( eg , cimetidine ) , due withdrawal drug anticonvulsant , benzodiazepine , barbiturate , hypnotic Subject history sleep disturbance , sleep apnea syndrome ( include obstructive sleep apnea ) , narcolepsy , sleep attacks/sudden onset sleep , myoclonus epilepsy either observed PSG ( local PSG evaluation ) evidence subject history Subject uncontrolled hypertension accord judgment investigator Subject additional clinically relevant concomitant disease , attention deficit hyperactivity disorder , polyneuropathy , akathisia , claudication , varicosis , muscle fasciculation , painful leg move toe , radiculopathy Subject central nervous system disease , Parkinson 's disease , dementia , progressive supranuclear paresis , multisystem atrophy , Huntington 's chorea , amyotrophic lateral sclerosis , Alzheimer 's disease . Subject prior history psychotic episode Subject history chronic alcohol drug abuse within previous 12 month Subject medical psychiatric condition , opinion investigator , jeopardize would compromise subject 's ability participate study Subject clinically relevant cardiac dysfunction and/or arrhythmia ( eg , suspect conduction system dysregulations , second third degree atrioventricular block , complete leave right bundle branch block , sick sinus syndrome , New York Heart Association Class III IV congestive heart failure , myocardial infarction within 12 month prior Screening [ Visit 1 ] ) Subject clinically relevant venous arterial peripheral vascular disease Subject malignant neoplastic disease require therapy within 12 month prior Screening ( Visit 1 ) Subject currently receive treatment follow drug class : neuroleptic , hypnotic , antidepressant , anxiolytic drug , anticonvulsive therapy , budipine , dopamine antagonist antiemetic ( except domperidone ) , opioids , benzodiazepine , monoamine oxidase ( MAO ) inhibitor , catecholOmethyltransferase ( COMT ) inhibitor , sedative antihistamine , psychostimulates , amphetamine . If subject receive therapy , Washout Period least 7 day prior Baseline ( Visit 2 ) require start treatment study Subject pregnant , nursing , woman childbearing potential surgically sterile , 2 year postmenopausal , consistently use 2 combined effective method contraception , include least 1 barrier method , unless sexually abstinent Subject shift worker perform continuous nondiseaserelated life condition allow regular sleep night At Screening Visit Baseline Visit subject symptomatic orthostatic hypotension Subject treat dopamine agonist within period 14 day prior Baseline Ldopa within 7 day prior Baseline Subject medical history indicate intolerability prior dopaminergic therapy ( pretreated ) Subject receive previous treatment Rotigotine Subject participate another study investigational drug device within 28 day prior Visit 2 ( Baseline ) currently participate another study investigational drug Subject know hypersensitivity component study medication , history significant skin hypersensitivity adhesive , know hypersensitivity transdermal medication , unresolved contact dermatitis Subject lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either Question 4 Question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
	<keyword>RLS</keyword>
	<keyword>Cardiovascular Risk</keyword>
	<keyword>Nocturnal Blood Pressure</keyword>
</DOC>